|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
|
US5160742A
(en)
*
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
|
IT1260505B
(it)
*
|
1992-06-01 |
1996-04-09 |
Poli Ind Chimica Spa |
Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
|
|
WO1995016451A1
(fr)
*
|
1992-06-22 |
1995-06-22 |
Franck Arno Gouchet |
Comprimes a liberation controlee de 4-asa
|
|
FR2692484B1
(fr)
*
|
1992-06-22 |
1995-06-30 |
Gouchet Franck |
Nouvelle forme galenique de 4-asa a liberation controlee.
|
|
AU670958B2
(en)
*
|
1992-08-05 |
1996-08-08 |
Mayne Pharma International Pty Ltd |
Pelletised pharmaceutical composition
|
|
EP0653935B1
(en)
*
|
1992-08-05 |
2002-05-08 |
F.H. FAULDING & CO. LIMITED |
Pelletised pharmaceutical composition
|
|
US5358502A
(en)
|
1993-02-25 |
1994-10-25 |
Pfizer Inc |
PH-triggered osmotic bursting delivery devices
|
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
IT1265092B1
(it)
*
|
1993-05-31 |
1996-10-30 |
Giuliani Spa |
Preparato per uso come integratore alimentare, o dietetico,a rilascio mirato nel colon
|
|
DE4332394A1
(de)
*
|
1993-09-23 |
1995-03-30 |
Falk Pharma Gmbh |
Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
|
|
US5523095A
(en)
*
|
1993-12-15 |
1996-06-04 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
|
|
US5536505A
(en)
*
|
1993-12-15 |
1996-07-16 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
|
|
AU689250B2
(en)
*
|
1994-04-22 |
1998-03-26 |
Astellas Pharma Inc. |
Colon-specific drug release system
|
|
AT403988B
(de)
*
|
1994-05-18 |
1998-07-27 |
Lannacher Heilmittel |
Festes orales retardpräparat
|
|
US5686106A
(en)
*
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
|
CA2240281C
(en)
*
|
1995-12-21 |
2007-02-27 |
Farmaceutisk Laboratorium Ferring A/S |
Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
|
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
|
US6245351B1
(en)
|
1996-03-07 |
2001-06-12 |
Takeda Chemical Industries, Ltd. |
Controlled-release composition
|
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
AUPO247496A0
(en)
|
1996-09-23 |
1996-10-17 |
Resmed Limited |
Assisted ventilation to match patient respiratory need
|
|
WO1998026767A2
(en)
*
|
1996-12-17 |
1998-06-25 |
Poli Industria Chimica S.P.A. |
Site-specific controlled release dosage formulation for mesalamine
|
|
WO1998027967A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Dumex-Alpharma A/S |
Release-controlled coated tablets
|
|
US5891474A
(en)
*
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
US5788987A
(en)
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
|
DK1017392T3
(da)
*
|
1997-09-25 |
2002-10-21 |
Bayer Ag |
Lægemiddel
|
|
US6974590B2
(en)
|
1998-03-27 |
2005-12-13 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
|
US20030091629A1
(en)
*
|
1998-03-27 |
2003-05-15 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
|
US6962717B1
(en)
|
1999-01-29 |
2005-11-08 |
Disphar International B.V. |
Pharmaceutical compositions
|
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
|
RU2246293C2
(ru)
|
1999-06-14 |
2005-02-20 |
Космо С.П.А. |
Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
|
|
US8895064B2
(en)
|
1999-06-14 |
2014-11-25 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
|
US7897140B2
(en)
*
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
US6451345B1
(en)
|
2000-01-20 |
2002-09-17 |
Eurand Pharmaceuticals Ltd. |
Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
|
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
|
IT1318625B1
(it)
*
|
2000-07-14 |
2003-08-27 |
Roberto Valducci |
Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
|
|
AU2001284434A1
(en)
|
2000-09-06 |
2002-03-22 |
Mitsubishi Pharma Corporation |
Granular preparations for oral administration
|
|
RU2191782C2
(ru)
*
|
2000-09-21 |
2002-10-27 |
Институт нефтехимии и катализа АН РБ и УНЦ РАН |
Способ получения модифицированной гиалуроновой кислоты
|
|
CA2359812C
(en)
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
|
WO2003045356A1
(en)
*
|
2000-11-20 |
2003-06-05 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings
|
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
|
TR200300731T2
(tr)
|
2000-11-28 |
2004-08-23 |
Fmc Corporation |
Yenebilir PGA kaplama bileşimi
|
|
US20030190360A1
(en)
|
2001-03-13 |
2003-10-09 |
Baichwal Anand R. |
Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
|
|
RU2324475C2
(ru)
*
|
2001-04-10 |
2008-05-20 |
Сан Фармасьютикал Индастриз Лимитед |
Состав, выделяемый в импульсном режиме в заданное время
|
|
KR20010069756A
(ko)
*
|
2001-05-08 |
2001-07-25 |
유형선 |
소염진통제인 아세메타신을 함유하며 장관내 특히대장에서의 약물 방출 속도가 조절되는 약물 전달 체계에대한 약제학적 경구용 조성물 및 그에 대한 제조방법
|
|
US20030068356A1
(en)
*
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
|
US9358214B2
(en)
*
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
AR036797A1
(es)
|
2001-10-15 |
2004-10-06 |
Ferring Bv |
Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
|
|
EP1446110A2
(en)
*
|
2001-10-16 |
2004-08-18 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
EP1455751A1
(en)
*
|
2001-12-20 |
2004-09-15 |
Pharmacia Corporation |
Zero-order sustained released dosage forms and method of making the same
|
|
RU2220716C1
(ru)
*
|
2002-04-24 |
2004-01-10 |
Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова |
Способ получения микрокапсул, содержащих живые микроорганизмы
|
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
|
CA2490692A1
(en)
|
2002-06-27 |
2004-01-08 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
EP1606291A2
(en)
*
|
2002-07-02 |
2005-12-21 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its dervatives
|
|
GB0217056D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Ass Octel |
Use
|
|
AU2003251377A1
(en)
*
|
2002-08-14 |
2004-03-03 |
Quest International Services B.V. |
Compositions comprising encapsulated material
|
|
EP1393706A1
(en)
*
|
2002-08-14 |
2004-03-03 |
Quest International B.V. |
Fragranced compositions comprising encapsulated material
|
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
TWI355276B
(en)
*
|
2003-01-14 |
2012-01-01 |
Akira Tsuji |
Gastrointestinal absorption enhancer mediated by p
|
|
BRPI0408805A
(pt)
*
|
2003-03-31 |
2006-03-28 |
Pliva Lachema As |
composição farmacêutica contendo complexo de platina e método de fabricação da mesma
|
|
US20070042143A1
(en)
|
2003-04-23 |
2007-02-22 |
Ferring B.V. |
Sachet for a pharmaceutical composition
|
|
WO2004099162A1
(en)
*
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Polycyclic diazodioxide-based bcl-2 protein antagonist
|
|
WO2004099158A1
(en)
*
|
2003-04-30 |
2004-11-18 |
Ricerca Biosciences, Llc. |
Monocyclic diazodioxide based bcl-2 protein antagonists
|
|
CN102584813B
(zh)
*
|
2003-05-14 |
2016-07-06 |
Ngc药物公司 |
化合物及其在调节淀粉样蛋白β中的用途
|
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
|
US7825106B2
(en)
|
2003-09-03 |
2010-11-02 |
Agi Therapeutics Ltd. |
Modified release formulations and methods of treating inflammatory bowel disease
|
|
US7737133B2
(en)
|
2003-09-03 |
2010-06-15 |
Agi Therapeutics Ltd. |
Formulations and methods of treating inflammatory bowel disease
|
|
CA2539051C
(en)
|
2003-09-19 |
2014-08-12 |
Penwest Pharmaceuticals Co. |
Delayed release dosage forms
|
|
CA2537103C
(en)
|
2003-11-04 |
2010-01-19 |
Shire Laboratories, Inc. |
Once daily dosage forms of trospium
|
|
US8709476B2
(en)
|
2003-11-04 |
2014-04-29 |
Supernus Pharmaceuticals, Inc. |
Compositions of quaternary ammonium compounds containing bioavailability enhancers
|
|
EP1547601A1
(en)
|
2003-12-23 |
2005-06-29 |
Ferring B.V. |
Coating method
|
|
WO2005065317A2
(en)
|
2003-12-31 |
2005-07-21 |
Cima Labs Inc. |
Effervescent oral fentanyl dosage form
|
|
US20050142197A1
(en)
*
|
2003-12-31 |
2005-06-30 |
Cima Labs Inc. |
Generally linear effervescent oral fentanyl dosage form and methods of administering
|
|
ATE500821T1
(de)
*
|
2003-12-31 |
2011-03-15 |
Cima Labs Inc |
Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
|
|
US7670624B2
(en)
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
JP2005272347A
(ja)
*
|
2004-03-24 |
2005-10-06 |
Ohara Yakuhin Kogyo Kk |
固形製剤の製造方法
|
|
US7868033B2
(en)
|
2004-05-20 |
2011-01-11 |
Foldrx Pharmaceuticals, Inc. |
Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
WO2006009602A2
(en)
|
2004-06-16 |
2006-01-26 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
|
WO2006009876A2
(en)
*
|
2004-06-17 |
2006-01-26 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
JP2008505916A
(ja)
*
|
2004-07-09 |
2008-02-28 |
メタバシス・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの酸素／窒素複素環阻害剤
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
NZ588431A
(en)
|
2004-09-17 |
2012-02-24 |
Whitehead Biomedical Inst |
Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
|
|
US20060067889A1
(en)
*
|
2004-09-27 |
2006-03-30 |
Light Sciences Corporation |
Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
NZ589750A
(en)
|
2004-10-21 |
2012-07-27 |
Aptalis Pharmatech Inc |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
|
US9149439B2
(en)
*
|
2005-03-21 |
2015-10-06 |
Sandoz Ag |
Multi-particulate, modified-release composition
|
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
|
WO2008051197A2
(en)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
EP2013182B1
(en)
*
|
2006-03-13 |
2013-09-04 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones as gsk-3 inhibitors
|
|
CN101460161A
(zh)
*
|
2006-03-29 |
2009-06-17 |
弗尔德里克斯制药股份有限公司 |
α-突触核蛋白毒性的抑制
|
|
JP5457830B2
(ja)
|
2006-04-03 |
2014-04-02 |
オディディ，イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
US20080076743A1
(en)
|
2006-08-03 |
2008-03-27 |
Nitec Pharma Ag |
Delayed-Release Glucocorticoid treatment of Rheumatoid Disease
|
|
TWI405771B
(zh)
|
2006-08-28 |
2013-08-21 |
Kyowa Hakko Kirin Co Ltd |
具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
|
|
CA2661172A1
(en)
*
|
2006-09-04 |
2008-05-29 |
Panacea Biotec Limited |
Programmable buoyant delivery technology
|
|
PL2066662T3
(pl)
|
2006-09-21 |
2013-05-31 |
Kyorin Seiyaku Kk |
Inhibitory hydrolaz serynowych
|
|
CN101687788A
(zh)
|
2006-10-19 |
2010-03-31 |
奥斯拜客斯制药有限公司 |
取代的吲哚
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
EP2121676A1
(en)
|
2006-12-19 |
2009-11-25 |
Auspex Pharmaceuticals, Inc. |
Preperation and utility of ccr5 inhibitors
|
|
CA2671766A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
PT2144604E
(pt)
*
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
|
HRP20161581T1
(hr)
|
2007-03-15 |
2016-12-30 |
Auspex Pharmaceuticals, Inc. |
DEUTERIRANI d9-VENLAFAKSI
|
|
AU2008241470B2
(en)
|
2007-04-16 |
2013-11-07 |
Corium Pharma Solutions, Inc. |
Solvent-cast microneedle arrays containing active
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
PT2152250T
(pt)
*
|
2007-05-07 |
2019-12-12 |
Evonik Operations Gmbh |
Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco
|
|
EP2170062A4
(en)
*
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
|
|
MX2010002667A
(es)
*
|
2007-09-11 |
2010-04-01 |
Activx Biosciences Inc |
Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
|
|
CN101855229A
(zh)
|
2007-09-12 |
2010-10-06 |
埃迪威克斯生物科学公司 |
作为gsk-3抑制剂的螺环状氨基喹诺酮
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
WO2009048607A1
(en)
|
2007-10-10 |
2009-04-16 |
Corium International, Inc. |
Vaccine delivery via microneedle arrays
|
|
CA2702356C
(en)
*
|
2007-10-12 |
2014-02-11 |
Takeda Pharmaceuticals North America, Inc. |
Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
|
|
US8802156B2
(en)
|
2007-11-14 |
2014-08-12 |
Laboratorios Farmacéuticos Rovi, S.A. |
Pharmaceutical forms for the release of active compounds
|
|
AU2008327615B2
(en)
|
2007-11-21 |
2014-08-21 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
|
|
KR101601997B1
(ko)
|
2008-03-17 |
2016-03-17 |
암비트 바이오사이언시즈 코포레이션 |
Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
|
|
US20120034157A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
|
CN101658533A
(zh)
*
|
2008-08-29 |
2010-03-03 |
首都医科大学宣武医院 |
抗肿瘤药物的干细胞递送
|
|
WO2010040113A1
(en)
|
2008-10-03 |
2010-04-08 |
Salix Pharmaceuticals, Ltd. |
Compositions and methods for the treatment of bowel diseases with granulated mesalamine
|
|
NZ592673A
(en)
*
|
2008-11-13 |
2013-01-25 |
Giuliani Int Ltd |
Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
|
|
TWI494108B
(zh)
*
|
2009-01-26 |
2015-08-01 |
Nitec Pharma Ag |
糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
|
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
EP2401267B1
(en)
|
2009-02-27 |
2014-01-15 |
Ambit Biosciences Corporation |
Jak kinase modulating quinazoline derivatives and their use in methods
|
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
|
WO2010105016A1
(en)
|
2009-03-11 |
2010-09-16 |
Ambit Biosciences Corp. |
Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
|
|
CA2755120C
(en)
*
|
2009-03-11 |
2017-05-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
TW201038567A
(en)
|
2009-03-27 |
2010-11-01 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
KR101687144B1
(ko)
|
2009-04-22 |
2016-12-15 |
액시킨 파마수티컬스 인코포레이티드 |
2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
|
|
SG2014005110A
(en)
|
2009-04-22 |
2014-03-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide ccr3 antagonists
|
|
JP2012524789A
(ja)
|
2009-04-22 |
2012-10-18 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
２，５−二置換アリールスルホンアミドｃｃｒ３アンタゴニスト
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
AR080945A1
(es)
|
2009-07-07 |
2012-05-23 |
Pathway Therapeutics Inc |
Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
|
|
CA2767168C
(en)
|
2009-07-08 |
2019-04-09 |
Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
CN102470127A
(zh)
|
2009-08-19 |
2012-05-23 |
埃姆比特生物科学公司 |
联芳基化合物和其使用方法
|
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
RU2419422C1
(ru)
*
|
2009-11-05 |
2011-05-27 |
Федеральное государственное учреждение науки Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора РФ |
Способ коррекции функциональных нарушений билиарного тракта у детей, больных острыми кишечными инфекциями
|
|
WO2011057214A2
(en)
|
2009-11-09 |
2011-05-12 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
TWI471146B
(zh)
|
2009-12-02 |
2015-02-01 |
Aptalis Pharma Ltd |
菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
|
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
EP2538930B1
(en)
|
2010-02-23 |
2016-06-15 |
Da Volterra |
Formulations for oral delivery of adsorbents in the gut
|
|
CA2791964A1
(en)
|
2010-03-02 |
2011-09-09 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
MX336559B
(es)
|
2010-03-17 |
2016-01-25 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida.
|
|
WO2011140274A2
(en)
|
2010-05-04 |
2011-11-10 |
Corium International, Inc. |
Method and device for transdermal delivery of parathyroid hormone using a microprojection array
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
|
MX2012013879A
(es)
|
2010-06-01 |
2013-04-03 |
Biotheryx Inc |
Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
|
|
JP5855095B2
(ja)
|
2010-06-07 |
2016-02-09 |
ノボメディックス, エルエルシーNovomedix, Llc |
フラニル化合物およびその使用
|
|
NZ605860A
(en)
|
2010-07-19 |
2015-04-24 |
Summa Health System |
Use of vitamin c, and chromium-free vitamin k or 2-methyl-1,4-naphthalendione, and compositions thereof for treating a polycystic disease
|
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
MX2013002383A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Sales bromhidrato de una pirazolilaminoquinazolina.
|
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
AU2011296024B2
(en)
|
2010-09-01 |
2015-05-28 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
US8703943B2
(en)
|
2010-09-01 |
2014-04-22 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
CA2814011A1
(en)
|
2010-10-11 |
2012-04-19 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
|
EP2648676A4
(en)
|
2010-12-06 |
2016-05-04 |
Follica Inc |
METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
|
|
KR101940831B1
(ko)
|
2011-03-28 |
2019-01-21 |
메이 파마, 아이엔씨. |
(알파-치환된 아르알킬아미노 및 헤테로아릴알킬아미노)피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸, 이들을 함유하는 약학 조성물, 및 증식성 질병의 치료에 사용하기 위한 이들 화합물
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
WO2012135175A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
JP5813391B2
(ja)
*
|
2011-06-24 |
2015-11-17 |
日東電工株式会社 |
粒子製剤の製造方法
|
|
WO2012177962A1
(en)
|
2011-06-23 |
2012-12-27 |
Map Pharmaceuticals, Inc. |
Novel fluoroergoline analogs
|
|
US10154964B2
(en)
|
2011-09-07 |
2018-12-18 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
TWI650321B
(zh)
|
2011-10-14 |
2019-02-11 |
美商安比特生物科學公司 |
雜環化合物及其使用方法
|
|
EP2599477A1
(en)
|
2011-11-30 |
2013-06-05 |
Lunamed AG |
4-Phenylbutyric acid sustained release formulation
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
WO2013095708A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
|
JP2012107058A
(ja)
*
|
2012-02-27 |
2012-06-07 |
Warner Chilcott Co Llc |
複数のコーティングを有する医薬剤形
|
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
AU2013229990B2
(en)
*
|
2012-03-07 |
2017-07-06 |
Santarus, Inc. |
Controlled-release solid dosage forms of mesalamine
|
|
JP6134376B2
(ja)
|
2012-03-16 |
2017-05-24 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
３，５−ジアミノピラゾールキナーゼ阻害剤
|
|
BR112014024159A2
(pt)
|
2012-03-29 |
2017-06-20 |
Therabiome Llc |
Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
|
|
PL2844637T3
(pl)
|
2012-05-02 |
2018-09-28 |
Boehringer Ingelheim International Gmbh |
Podstawione 3-haloalliloaminowe inhibitory ssao i ich zastosowania
|
|
CN103417380B
(zh)
*
|
2012-05-22 |
2016-01-06 |
正和制药股份有限公司 |
具有肠溶膜衣的硬胶囊
|
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
AU2013295848B2
(en)
|
2012-07-25 |
2018-05-24 |
Celldex Therapeutics, Inc. |
Anti-KIT antibodies and uses thereof
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
WO2014033077A1
(en)
|
2012-08-28 |
2014-03-06 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
|
|
JP2015527396A
(ja)
|
2012-09-07 |
2015-09-17 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
同位体濃縮されたアリールスルホンアミドｃｃｒ３アンタゴニスト
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
CA2890177A1
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
|
KR102265808B1
(ko)
|
2012-12-21 |
2021-06-16 |
코리움, 인크. |
치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법
|
|
AU2014205324A1
(en)
|
2013-01-11 |
2015-07-30 |
Mayo Foundation For Medical Education And Research |
Vitamins C and K for treating polycystic diseases
|
|
EP2968887B1
(en)
|
2013-03-12 |
2022-05-04 |
Corium, Inc. |
Microprojection applicators
|
|
WO2014152338A1
(en)
|
2013-03-14 |
2014-09-25 |
Kabadi Mohan |
Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
|
|
WO2014152450A1
(en)
|
2013-03-15 |
2014-09-25 |
Warner Chilcott Company, Llc |
Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
|
|
EP2968116A1
(en)
|
2013-03-15 |
2016-01-20 |
Corium International, Inc. |
Microarray with polymer-free microstructures, methods of making, and methods of use
|
|
MX2015012433A
(es)
|
2013-03-15 |
2016-02-03 |
Corium Int Inc |
Matriz de microestructura para suministro de agentes activos.
|
|
JP2016512754A
(ja)
|
2013-03-15 |
2016-05-09 |
コリウム インターナショナル， インコーポレイテッド |
治療剤の送達のためのマイクロアレイ、使用方法および製造方法
|
|
CN105246458B
(zh)
|
2013-03-15 |
2020-09-15 |
考里安公司 |
用于治疗剂递送的微阵列及其使用方法
|
|
EP4194028A1
(en)
|
2013-03-15 |
2023-06-14 |
Corium Pharma Solutions, Inc. |
Multiple impact microprojection applicators
|
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
|
KR20160055170A
(ko)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 아세트아미드 화합물 및 이의 사용 방법
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015127351A1
(en)
|
2014-02-24 |
2015-08-27 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
KR20240064750A
(ko)
|
2014-03-20 |
2024-05-13 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス，インコーポレーテッド |
癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
|
EP3444011A1
(en)
|
2014-05-12 |
2019-02-20 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with emricasan
|
|
RS61678B1
(sr)
|
2014-05-28 |
2021-05-31 |
Agenus Inc |
Anti-gitr antitela i postupci za njihovu primenu
|
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
JP6543342B2
(ja)
|
2014-08-14 |
2019-07-10 |
アルハマドシャー，マモウン，エム． |
血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
|
|
EP3193828B8
(en)
|
2014-08-29 |
2023-04-05 |
Corium Pharma Solutions, Inc. |
Microstructure array for delivery of active agents
|
|
EP3188714A1
(en)
|
2014-09-04 |
2017-07-12 |
Corium International, Inc. |
Microstructure array, methods of making, and methods of use
|
|
EP3191100A4
(en)
|
2014-09-12 |
2018-05-30 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
KR102693806B1
(ko)
|
2014-12-11 |
2024-08-09 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
ES2862701T3
(es)
|
2014-12-22 |
2021-10-07 |
Univ Rockefeller |
Anticuerpos agonistas anti-MERTK y usos de los mismos
|
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
CN107405346A
(zh)
|
2015-01-20 |
2017-11-28 |
Xoc制药股份有限公司 |
异麦角灵化合物及其用途
|
|
BR112017015487A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
|
|
HK1247203A1
(zh)
|
2015-01-28 |
2018-09-21 |
上海复旦张江生物医药股份有限公司 |
取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
|
|
LT3265123T
(lt)
|
2015-03-03 |
2023-01-25 |
Kymab Limited |
Antikūnai, naudojimas ir būdai
|
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
|
CN107921032B
(zh)
|
2015-06-23 |
2021-09-24 |
纽罗克里生物科学有限公司 |
用于治疗神经学疾病或病症的vmat2抑制剂
|
|
WO2017004067A1
(en)
|
2015-06-29 |
2017-01-05 |
Corium International, Inc. |
Microarray for delivery of therapeutic agent, methods of use, and methods of making
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
JP7109360B2
(ja)
|
2015-10-30 |
2022-07-29 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
バルベナジン塩およびその多形体
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
CN108883103A
(zh)
|
2015-12-02 |
2018-11-23 |
阿斯特来亚治疗有限责任公司 |
哌啶基痛敏肽受体化合物
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CA3009169A1
(en)
|
2015-12-23 |
2017-06-29 |
Neurocrine Biosciences, Inc. |
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
KR20180101418A
(ko)
|
2015-12-31 |
2018-09-12 |
코나터스 파마슈티칼스, 인크. |
간 질환의 치료에서의 카스파제 억제제의 사용 방법
|
|
MX385964B
(es)
|
2016-01-08 |
2025-03-18 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
|
|
EP3808346B1
(en)
|
2016-01-08 |
2023-07-19 |
Celgene Corporation |
Antiproliferative compounds for use in the treatment of leukemia
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
JP2019510085A
(ja)
|
2016-03-08 |
2019-04-11 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
癌治療のためのナノ粒子ならびに方法および化合物
|
|
JP2019513151A
(ja)
|
2016-03-08 |
2019-05-23 |
ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
カンプトテシン誘導体及びその使用
|
|
CA3017797A1
(en)
|
2016-03-17 |
2017-09-21 |
Thiogenesis Therapeutics, Inc. |
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
|
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
RU2738114C2
(ru)
|
2016-04-19 |
2020-12-08 |
Конарис Рисёрч Инститьют Аг |
Пероральные фармацевтические композиции никотинамида
|
|
AR108231A1
(es)
*
|
2016-04-19 |
2018-08-01 |
Ferring Bv |
Composiciones farmacéuticas orales de mesalazina
|
|
EP4190357A1
(en)
|
2016-05-13 |
2023-06-07 |
Institut Pasteur |
Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
NZ749355A
(en)
|
2016-05-27 |
2023-04-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
US10919904B2
(en)
|
2016-08-17 |
2021-02-16 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
US20190201409A1
(en)
|
2016-09-19 |
2019-07-04 |
Mei Pharma, Inc. |
Combination therapy
|
|
TWI843168B
(zh)
|
2016-10-11 |
2024-05-21 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JP7045724B2
(ja)
|
2016-11-07 |
2022-04-01 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
CN110167542A
(zh)
|
2016-11-09 |
2019-08-23 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
|
WO2018102252A1
(en)
|
2016-11-30 |
2018-06-07 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
|
EA201991782A1
(ru)
|
2017-01-27 |
2021-09-23 |
Нейрокрин Байосайенсиз, Инк. |
Способы введения некоторых vmat2-ингибиторов
|
|
MX2021015220A
(es)
|
2017-02-17 |
2022-12-01 |
Eidos Therapeutics Inc |
Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
|
|
AU2018220515B2
(en)
|
2017-02-17 |
2022-06-30 |
DayLife LLC |
Universal antivenom
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
EP3601351A1
(en)
|
2017-03-27 |
2020-02-05 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
SMT202300243T1
(it)
|
2017-05-01 |
2023-11-13 |
Agenus Inc |
Anticorpi anti-tigit e relativi metodi d'uso
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
IL270654B2
(en)
*
|
2017-05-17 |
2024-07-01 |
Confluence Pharmaceuticals Llc |
Formulations of homotaurines and salts thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
US11560425B2
(en)
|
2017-06-27 |
2023-01-24 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating cancers
|
|
AU2018291082B2
(en)
|
2017-06-27 |
2025-05-29 |
Neuracle Science Co., Ltd. |
Anti-FAM19A5 antibodies and uses thereof
|
|
JP6904616B2
(ja)
|
2017-06-27 |
2021-07-21 |
ニューラクル サイエンス カンパニー リミテッド |
緑内障治療のための配列相同性を有するファミリー、メンバーａ５抗体の用途
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
EP4265257A1
(en)
|
2017-09-01 |
2023-10-25 |
East Carolina University |
Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
|
|
ES3024932T3
(en)
|
2017-09-20 |
2025-06-05 |
Thiogenesis Therapeutics Inc |
Compounds for the treatment of cysteamine sensitive disorders
|
|
EP3459528B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Preparation of solid dosage forms comprising antibodies by solution/suspension layering
|
|
CN111372567B
(zh)
|
2017-09-21 |
2024-03-15 |
纽罗克里生物科学有限公司 |
高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
|
|
WO2019069229A1
(en)
|
2017-10-02 |
2019-04-11 |
Neuracle Science Co., Ltd. |
USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
|
|
KR20200084864A
(ko)
|
2017-10-04 |
2020-07-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
면역조절성 올리고사카라이드
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2019074492A1
(en)
|
2017-10-10 |
2019-04-18 |
Obrien Christopher F |
METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
|
|
CN111315772A
(zh)
|
2017-10-31 |
2020-06-19 |
斯塔顿生物技术有限公司 |
抗apoc3抗体及其使用方法
|
|
EP3501503A1
(en)
|
2017-12-22 |
2019-06-26 |
Cosmo Technologies Ltd. |
Solid delivery composition
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
US11701334B2
(en)
|
2018-01-10 |
2023-07-18 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
UA130053C2
(uk)
|
2018-03-23 |
2025-10-29 |
Ейдос Терапьютікс, Інк. |
Спосіб лікування транстиретинового амілоїдозу із застосуванням ag10
|
|
WO2019207513A1
(en)
|
2018-04-24 |
2019-10-31 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
|
|
KR102585324B1
(ko)
|
2018-05-08 |
2023-10-10 |
주식회사 뉴라클제네틱스 |
항-fam19a5 항체의 아데노-연관 바이러스(aav) 전달
|
|
CN119569873A
(zh)
|
2018-05-10 |
2025-03-07 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
|
IL320987A
(en)
|
2018-08-15 |
2025-07-01 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
CN112804998A
(zh)
|
2018-08-17 |
2021-05-14 |
文涵治疗有限公司 |
Ag10的制剂
|
|
EP3860713A2
(en)
|
2018-10-03 |
2021-08-11 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
|
JP7211610B2
(ja)
|
2018-10-16 |
2023-01-24 |
ニューラクル サイエンス カンパニー リミテッド |
抗ｆａｍ１９ａ５抗体の用途
|
|
CA3119341A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
IT201800011120A1
(it)
|
2018-12-14 |
2020-06-14 |
Dpl Pharma S P A |
Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
|
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
|
KR102757347B1
(ko)
|
2018-12-27 |
2025-01-23 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
SG11202104217QA
(en)
|
2019-01-02 |
2021-05-28 |
Neuracle Science Co Ltd |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
MX2021010003A
(es)
|
2019-02-26 |
2021-12-10 |
Inspirna Inc |
Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
|
|
US11597703B2
(en)
|
2019-03-07 |
2023-03-07 |
Histogen, Inc. |
Caspase inhibitors and methods of use thereof
|
|
ES3036313T3
(en)
|
2019-05-20 |
2025-09-17 |
Nirvana Sciences Inc |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
WO2020236818A1
(en)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
US20220274922A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2021007474A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
CA3148226A1
(en)
|
2019-08-12 |
2021-02-18 |
Massachusetts Institute Of Technology |
Articles and methods for administration of therapeutic agents
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
AU2020335928A1
(en)
|
2019-08-30 |
2022-02-17 |
Agenus Inc. |
Anti-CD96 antibodies and methods of use thereof
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
CN114945409A
(zh)
|
2020-01-13 |
2022-08-26 |
新免疫技术有限公司 |
用il-7蛋白和双特异性抗体的组合治疗肿瘤的方法
|
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
AU2021217373A1
(en)
|
2020-02-05 |
2022-08-04 |
Neoimmunetech, Inc. |
Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
|
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
US20240025863A1
(en)
|
2020-09-16 |
2024-01-25 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022087335A1
(en)
|
2020-10-23 |
2022-04-28 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
US20240101629A1
(en)
|
2020-11-02 |
2024-03-28 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
IL302482A
(en)
|
2020-11-05 |
2023-06-01 |
Neoimmunetech Inc |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
AU2021402911A1
(en)
|
2020-12-14 |
2023-07-06 |
Biotheryx, Inc. |
Pde4 degraders, pharmaceutical compositions, and therapeutic applications
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20220280585A1
(en)
*
|
2021-03-05 |
2022-09-08 |
Poopermints, LLC |
Pharmaceutical composition containing champignon extract and peppermint and methods of use thereof
|
|
JP2024510196A
(ja)
|
2021-03-10 |
2024-03-06 |
ダイス・モレキュールズ・エスブイ・インコーポレイテッド |
アルファｖベータ６およびアルファｖベータ１インテグリン阻害剤およびその使用
|
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
JP2024520676A
(ja)
|
2021-06-02 |
2024-05-24 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ｎｒ４ａ３欠損免疫細胞及びその使用
|
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
|
WO2022266249A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
WO2022266248A1
(en)
|
2021-06-16 |
2022-12-22 |
Biotheryx, Inc. |
Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
EP4410311A4
(en)
|
2021-09-29 |
2025-12-17 |
Nbios Inc |
FUSION PROTEIN WITH WINDED COIL CORE
|
|
JP2024539134A
(ja)
|
2021-10-22 |
2024-10-28 |
プロセッタ バイオサイエンシズ， インク． |
新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
|
|
JP2024540411A
(ja)
|
2021-11-08 |
2024-10-31 |
プロジェントス・セラピューティクス・インコーポレイテッド |
血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
|
|
US20250099542A1
(en)
|
2021-12-30 |
2025-03-27 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
JP2025501308A
(ja)
|
2022-01-03 |
2025-01-17 |
ライラック セラピューティクス， インク． |
非環式チオールプロドラッグ
|
|
AU2022441090A1
(en)
|
2022-02-17 |
2024-08-22 |
Novelty Nobility Inc. |
Antibody-drug conjugate.
|
|
CN118922189A
(zh)
|
2022-03-02 |
2024-11-08 |
线粒体能量有限公司 |
衍生自烟酸和核糖的新型前药
|
|
CA3254863A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
DYSTROPHIN EXON-SKIPPING OLIGONUCLEOTIDES
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
AU2023252917A1
(en)
|
2022-04-14 |
2024-11-28 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
IL316794A
(en)
|
2022-05-10 |
2025-01-01 |
Biotheryx Inc |
CDK protease inhibitors, pharmaceuticals and therapeutic applications
|
|
CA3253951A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
NR4A3 Targeted Polynucleotides and Their Uses
|
|
CA3267079A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DOUBLE CK1α/GSPT1 DEGRADATION COMPOUNDS
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
JP2025537484A
(ja)
|
2022-10-21 |
2025-11-18 |
ダイアゴナル・セラピューティクス・インコーポレイテッド |
Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
|
|
EP4608834A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4608839A1
(en)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
KR20250089492A
(ko)
|
2022-11-07 |
2025-06-18 |
네오이뮨텍, 인코퍼레이티드 |
비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
|
|
EP4626865A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
AU2024240129A1
(en)
|
2023-03-17 |
2025-10-09 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
AU2024254039A1
(en)
|
2023-04-07 |
2025-10-02 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|
|
CN121127500A
(zh)
|
2023-04-07 |
2025-12-12 |
达科纳治疗有限公司 |
针对激活素a受体样1型(alk1)的双特异性激动性抗体
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
WO2024233303A1
(en)
|
2023-05-05 |
2024-11-14 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
CN121263415A
(zh)
|
2023-05-09 |
2026-01-02 |
普罗根托斯治疗公司 |
杂环化合物及其用途
|
|
US20250019450A1
(en)
|
2023-05-19 |
2025-01-16 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025046298A2
(en)
|
2023-09-01 |
2025-03-06 |
iTeos Belgium SA |
Anti-trem2 antibodies and methods of use
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
US20250179197A1
(en)
|
2023-10-23 |
2025-06-05 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|